Tags: Samsung BiologicsKurma PartnersbiologicsBiosimilar Approval Pathways,FDA Biosimilar Designations,Biosimilar vs Biologics,Biosimilars Safety and Efficacy,Specialty Pharmacy Biosimilars Impact,Biosimilar Integration Best Practices,Biosimilar Patient Education,Provider Collaboration on Biosimilars,Biosimilar Staff Training,High-Cost Biosimilar Inventory Management,Just-in-Time Inventory for Biologics,Biosimilar Utilization Trends,Switching Between Biosimilars and Biologics,Automatic Biosimilar Substitutions,Interchangeability of Biosimilars,Collaborative Practice Agreements for Biosimilars,Biosimilar Substitution Regulations by State,Pharmacy Regulations for Biosimilar Switching,Impact of Biosimilars on Treatment Paradigms,Cost Effectiveness of Biosimilars,Pharmacy Provider Collaboration Strategies,Biosimilar Copay Assistance Programs,Patient Education on Copay Programs,Pharmacy Management of Biosimilar Stock,Operationalizing Biosimilars in Specialty Pharmacy,Navigating Biosimilar Approval Processes,Best Practices for Biosimilar Integration,Pharmacy and Provider Education on Biosimilars,Impact of Biosimilars on Specialty Pharmacy Care,Managing Biosimilar Inventory in Specialty Pharmaciesbiochemistry, collagen, keratin, microbiology, proteins, spiders, synthetic biology
Journalists covering computational biology, genetics, Human Genome Project, non-coding RNA
The Scientist, New Scientist, Nature, STAT News and others - 104 journalists.